Literature DB >> 23569344

Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection.

Jia Xu1, Yu-Hai Bian, Xin Jin, Hui Cao.   

Abstract

AIM: To compare the prognostic assessment of lymph node ratio and absolute number based staging system for gastric cancer after D2 resection.
METHODS: The clinical, pathologic, and long-term follow-up data of 427 patients with gastric cancer that underwent D2 curative gastrectomy were retrospectively analyzed. The relationships between the metastatic lymph node ratio (MLR), log odds of positive lymph nodes (LODDS), and positive lymph nodes (pN) staging methods and the long-term prognoses of the patients were compared. In addition, the survival curves, accuracy, and homogeneity were compared with stratification to evaluate the prognostic assessment of the 3 methods when the number of tested lymph nodes was insufficient (< 10 and 10-15).
RESULTS: MLR [hazard ratio (HR) = 1.401, P = 0.012], LODDS (HR = 1.012, P = 0.034), and pN (HR = 1.376, P = 0.005) were independent risk factors for gastric cancer patients. The receiver operating characteristic (ROC) curves showed that the prognostic accuracy of the 3 methods was comparable (P > 0.05). Spearman correlation analysis confirmed that MLR, LODDS, and pN were all positively correlated with the total number of tested lymph nodes. When the number of tested lymph node was < 10, the value of survival curves staged by MLR and LODDS was superior to those of pN staging. However, the difference in survival curves between adjacent stages was not significant. In addition, the survival rate of stage 4 patients using the MLR and LODDS staging methods was 26.7% and 27.3% with < 10 lymph node, respectively which were significantly higher than the survival rate of patients with > 15 tested lymph nodes (< 4%). The ROC curve showed that the accuracy of the prognostic assessment of MLR, LODDS, and pN staging methods was comparable (P > 0.05), and the area under the ROC curve of all 3 methods were increased progressively with the enhanced levels of examined lymph nodes. In addition, the homogeneity of the 3 methods in patients with ≤ 15 tested lymph nodes also showed no significant difference.
CONCLUSION: Neither MLR or LODDS could reduce the staging bias. A sufficient number of tested lymph nodes is key to ensure an accurate prognosis for patients underwent D2 radical gastrectomy.

Entities:  

Keywords:  Gastric cancer; Lymph node metastasis; Metastatic lymph node ratio; Prognosis

Mesh:

Year:  2013        PMID: 23569344      PMCID: PMC3613114          DOI: 10.3748/wjg.v19.i12.1975

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  The superiority of ratio-based lymph node staging in gastric carcinoma.

Authors:  Kentaro Inoue; Yasushi Nakane; Hitoshi Iiyama; Mutsuya Sato; Tatsuya Kanbara; Koji Nakai; Syunichiro Okumura; Keigo Yamamichi; Koshiro Hioki
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

2.  Prognostic impact of positive lymph node ratio in gastric carcinoma.

Authors:  Orhan Celen; Emin Yildirim; Uğur Berberoglu
Journal:  J Surg Oncol       Date:  2007-08-01       Impact factor: 3.454

3.  Adjustment of N stages of gastric cancer by the ratio between the metastatic and examined lymph nodes.

Authors:  Chan-Young Kim; Doo-Hyun Yang
Journal:  Ann Surg Oncol       Date:  2009-05-12       Impact factor: 5.344

Review 4.  Epidemiology, pathology and clinical management of multiple gastric cancers: a mini-review.

Authors:  Jiayuan Peng; Yu Wang
Journal:  Surg Oncol       Date:  2010-06-20       Impact factor: 3.279

5.  Outcome of ratio of lymph node metastasis in gastric carcinoma.

Authors:  Etsuro Bando; Yutaka Yonemura; Keizo Taniguchi; Sachio Fushida; Takashi Fujimura; Koichi Miwa
Journal:  Ann Surg Oncol       Date:  2002-10       Impact factor: 5.344

6.  Evaluation of the New International Union Against Cancer TNM staging for gastric carcinoma.

Authors:  H Katai; K Yoshimura; K Maruyama; M Sasako; T Sano
Journal:  Cancer       Date:  2000-04-15       Impact factor: 6.860

7.  The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients.

Authors:  Z Sun; G-L Zhu; C Lu; P-T Guo; B-J Huang; K Li; Y Xu; De-Ming Li; Z-N Wang; H-M Xu
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

Review 8.  Chemotherapy for metastatic gastric cancer: past, present, and future.

Authors:  Atsushi Ohtsu
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

9.  D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Yukinori Kurokawa; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

10.  Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial.

Authors:  M Degiuli; M Sasako; M Calgaro; M Garino; F Rebecchi; M Mineccia; D Scaglione; D Andreone; A Ponti; F Calvo
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

View more
  14 in total

1.  Usefulness of the log odds of positive lymph nodes to predict and discriminate prognosis in gastric carcinomas.

Authors:  A Calero; J Escrig-Sos; F Mingol; A Arroyo; D Martinez-Ramos; M de Juan; J L Salvador-Sanchis; E Garcia-Granero; R Calpena; F J Lacueva
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

2.  Log odds of positive lymph nodes (LODDS): what are their role in the prognostic assessment of gastric adenocarcinoma?

Authors:  Paolo Aurello; Niccolò Petrucciani; Giuseppe R Nigri; Marco La Torre; Paolo Magistri; Simone Tierno; Francesco D'Angelo; Giovanni Ramacciato
Journal:  J Gastrointest Surg       Date:  2014-05-20       Impact factor: 3.452

Review 3.  N staging: the role of the pathologist.

Authors:  Costanza De Marco; Alberto Biondi; Riccardo Ricci
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-20

4.  Characterization of lymph node metastasis and its clinical significance in the surgical treatment of gastric cancer.

Authors:  Chao-Hui Zuo; Hailong Xie; Jingshi Liu; Xiao-Xin Qiu; Jin-Guan Lin; Xiao Hua; Ang Qin
Journal:  Mol Clin Oncol       Date:  2014-06-03

5.  Comparison of different lymph node staging systems in prognosis of gastric cancer: a bi-institutional study from Hungary.

Authors:  Dezső Tóth; Adrienn Bíró; Zsolt Varga; Miklós Török; Péter Árkosy
Journal:  Chin J Cancer Res       Date:  2017-08       Impact factor: 5.087

6.  Comparison of prognostic nomograms based on different nodal staging systems in patients with resected gastric cancer.

Authors:  Zi-Xian Wang; Miao-Zhen Qiu; Yu-Ming Jiang; Zhi-Wei Zhou; Guo-Xin Li; Rui-Hua Xu
Journal:  J Cancer       Date:  2017-03-12       Impact factor: 4.207

Review 7.  Alternative staging of regional lymph nodes in gastric cancer.

Authors:  Antoni M Szczepanik; Agata Paszko; Miroslaw Szura; Thecla Scully-Horner; Jan Kulig
Journal:  Prz Gastroenterol       Date:  2016-07-27

8.  Different lymph node staging systems in patients with gastric cancer from Korean: What is the best prognostic assessment tool?

Authors:  Jin Won Lee; Bandar Ali; Cho Hyun Park; Kyo Young Song
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Lymph node staging systems in patients with gastric cancer treated with D2 resection plus adjuvant chemotherapy.

Authors:  Yi-Xin Zhou; Lu-Ping Yang; Zi-Xian Wang; Ming-Ming He; Jing-Ping Yun; Dong-Sheng Zhang; Feng Wang; Rui-Hua Xu
Journal:  J Cancer       Date:  2018-01-06       Impact factor: 4.207

Review 10.  Management of pancreatic head adenocarcinoma: From where to where?

Authors:  Kemal Dolay; Fatma Umit Malya; Sami Akbulut
Journal:  World J Gastrointest Surg       Date:  2019-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.